Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | NEK2 | P51955 | 2/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965560 | 0.84 | KDM4E (0.54) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL16398202 | 0.83 | NEK2 (0.52) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL20037680 | 0.83 | NOTUM (0.50) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL23103150 | 0.82 | NOTUM (0.49) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL23114831 | 0.82 | PRMT5 (0.47) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL25146908 | 0.82 | ACACB (0.49) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL1441410 | 0.82 | CHRNB2 (0.54) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL20249117 | 0.82 | HRH3 (0.49) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL21180884 | 0.81 | MAPT (0.62) | KDM4EHPGDCYP2C19LMNA | |
| SCHEMBL20037588 | 0.81 | NOTUM (0.46) | KDM4EUSP2HPGDNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| EP-2401279-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | Vantia Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | KDM4E 2389/4885USP2 3478/4885HPGD 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.